Tuomo Alanko

Docrates Cancer Center — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index5.3kcitations128works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(83), Cancer Research and Treatments(73), CAR-T cell therapy research(44), Viral Infectious Diseases and Gene Expression in Insects(41), Cancer Immunotherapy and Biomarkers(14)

Publications128 total

Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors
Molecular Therapy·2026Open Access
1579P Fully intravenous split-dose administration of oncolytic adenovirus TILT-123 in advanced solid tumors
Annals of Oncology·2025
1203P Clinical correlations and long-term survival in PROTA: Platinum-resistant or refractory ovarian cancer treated with an oncolytic adenovirus encoding TNF and IL2 in combination with pembrolizumab
Annals of Oncology·2025
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
Journal of Clinical Oncology·2025
Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab
Cancer Research·2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
Cancer Gene Therapy·2025· 2 citedOpen Access
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
Nature Communications·2025· 15 citedOpen Access
Safety And Immunological Activity Of A Oncolytic Adenovirus Expressing TNFa And IL-2 In Combination With Pembrolizumab In Platinum-Resistant Or Refractory Ovarian Cancer Patients
International Journal of Gynecological Cancer·2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2
Immuno-Oncology Technology·2024Open Access
163P Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Immuno-Oncology Technology·2024Open Access
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
Journal of Experimental & Clinical Cancer Research·2024· 13 citedOpen Access
722 Immunoprofiling and correlative analysis from PROTA: a phase I trial combining an oncolytic adenovirus encoding TNFα and IL2 with pembrolizumab for platinum-resistant or refractory ovarian cancer
Regular and Young Investigator Award Abstracts·2024Open Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Akseli Hemminki(20), Kalevi Kairemo(11), Santeri A. Pakola(10), Elise Jirovec(10), Suvi Sorsa(10), João M. Santos(10), Kaarina Partanen(9), James H.A. Clubb(9), Lyna Haybout(9), Tatiana V. Kudling(9), Dafne C.A. Quixabeira(8), Víctor Cervera-Carrascón(8), Petri Bono(7), Emmanuel S. Antonarakis(7), Marine Gross‐Goupil(7), Jeffrey C. Goh(7), Ulka N. Vaishampayan(7), Ronald de Wit(7), Satoshi Fukasawa(7), Johann S. de Bono(7)